These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2737671)

  • 21. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
    Kreipe HH
    Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective evaluation of the clinical and laboratory data from 300 patients of various hematological malignancies with chromosome 3 abnormalities.
    Liu D; Zhang Y; Chen S; Pan J; He X; Liang J; Chen Z
    Cancer Genet; 2015 Jun; 208(6):333-40. PubMed ID: 26032184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
    So CC; Ma ES; Wan TS; Yip SF; Chan LC
    Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
    [No Abstract]   [Full Text] [Related]  

  • 25. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders.
    Campbell LJ; Garson OM
    Leukemia; 1994 Jan; 8(1):67-71. PubMed ID: 8289501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal analysis of human leukemias by molecular genetic approaches.
    Bartram CR; Janssen JW
    Haematol Blood Transfus; 1990; 33():17-22. PubMed ID: 2182409
    [No Abstract]   [Full Text] [Related]  

  • 27. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy.
    Heinrichs S; Conover LF; Bueso-Ramos CE; Kilpivaara O; Stevenson K; Neuberg D; Loh ML; Wu WS; Rodig SJ; Garcia-Manero G; Kantarjian HM; Look AT
    Elife; 2013 Jul; 2():e00825. PubMed ID: 23878725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Location of the X inactivation center in primates and other mammals.
    Flejter WL; Van Dyke DL; Weiss L
    Hum Genet; 1986 Sep; 74(1):63-6. PubMed ID: 3759086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal bone marrow chromosome studies in potential leukemic myeloid disorders.
    Lisker R; Cobo de Gutiérrez A; Velázquez-Ferrari M
    Cancer; 1973 Mar; 31(3):509-15. PubMed ID: 4693582
    [No Abstract]   [Full Text] [Related]  

  • 30. [A Dutch chromosome abnormality in myelodysplasia?].
    Scheres JM; Hustinx TW; Geraedts JP; Leeksma CH; Holdrinet RS
    Ned Tijdschr Geneeskd; 1985 Sep; 129(37):1783-7. PubMed ID: 4069238
    [No Abstract]   [Full Text] [Related]  

  • 31. Abnormalities of chromosome 1 in myeloproliferative disorders.
    Rowley JD
    Cancer; 1975 Nov; 36(5):1748-57. PubMed ID: 1192363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder.
    O'Reilly J; Crawford J; Uzaraga J; Cannell P
    Cancer Genet Cytogenet; 2005 Apr; 158(1):81-3. PubMed ID: 15771910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cytogenetic study of 93 myelodysplastic syndromes].
    Solé F; Woessner S; Florensa L; Pérez-Losada A; Acín P; Besses C; García-Eroles L; Sans-Sabrafen J
    Med Clin (Barc); 1998 Jan; 110(3):94-8. PubMed ID: 9534140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of hematologic diseases using conventional karyotyping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH).
    Wilkens L; Tchinda J; Burkhardt D; Nolte M; Werner M; Georgii A
    Hum Pathol; 1998 Aug; 29(8):833-9. PubMed ID: 9712425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Significance, diagnosis and prognosis in the cytogenetic analysis in acute leukemias and myelodysplastic syndromes].
    Jotterand Bellomo M
    Ther Umsch; 1996 Feb; 53(2):103-10. PubMed ID: 8629259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The clinical significance of chromosome study in leukemia].
    Mitelman F
    Lakartidningen; 1975 Sep; 72(37):3417-21. PubMed ID: 1057724
    [No Abstract]   [Full Text] [Related]  

  • 37. Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia.
    Najfeld V; Tripodi J; Scalise A; Silverman LR; Silver RT; Fruchtman S; Hoffman R
    Br J Haematol; 2010 Nov; 151(3):288-91. PubMed ID: 20738298
    [No Abstract]   [Full Text] [Related]  

  • 38. Implications for the use of X-chromosome inactivation patterns and their relevance to the myeloproliferative disorders.
    Gilbert HL; Acharya J; Pearson TC
    Eur J Haematol; 1998 Oct; 61(4):282-3. PubMed ID: 9820638
    [No Abstract]   [Full Text] [Related]  

  • 39. Breakpoint cluster region, immunoglobulin, and T-cell receptor gene rearrangement analysis in juvenile chronic myelogenous leukemia.
    Farhi DC; Luckey CN; Siddiqui AM
    Mod Pathol; 1995 May; 8(4):389-93. PubMed ID: 7567936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.